1,334
Views
6
CrossRef citations to date
0
Altmetric
Short Report

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine

, &
Pages 645-648 | Received 29 Jun 2016, Accepted 21 Sep 2016, Published online: 23 Dec 2016

References

  • Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7; PMID:6135869; http://dx.doi.org/10.1016/S0140-6736(83)90340-9
  • Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001; 19:2688-91; PMID:11257410; http://dx.doi.org/10.1016/S0264-410X(00)00554-5
  • Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012; 30(Suppl 2):B87-97; PMID:22607904; http://dx.doi.org/10.1016/j.vaccine.2012.01.033
  • Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins BA, Rosenstein NE. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol 2005; 43:4811-4; PMID:16145146; http://dx.doi.org/10.1128/JCM.43.9.4811-4814.2005
  • Boutet R, Stuart JM, Kaczmarski EB, Gray SJ, Jones DM, Andrews N. Risk of laboratory-acquired meningococcal disease. J Hosp Infect 2001; 49:282-4; PMID:11740877; http://dx.doi.org/10.1053/jhin.2001.1084
  • Borrow R, Findlow J, Gray S, Taylor S, Kaczmarski E. Safe laboratory handling of Neisseria meningitidis. J Infect 2014; 68:305-12; PMID:24440738; http://dx.doi.org/10.1016/j.jinf.2014.01.003
  • Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011; 7:646-53; PMID:21904120; http://dx.doi.org/10.4161/hv.7.6.15482
  • Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011; 18:483-6; PMID:21177912; http://dx.doi.org/10.1128/CVI.00304-10
  • Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine 2015; 33:3322-30; PMID:26025807; http://dx.doi.org/10.1016/j.vaccine.2015.05.027
  • McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM, et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J 2014; 33:760-6; PMID:24722351; http://dx.doi.org/10.1097/INF.0000000000000327
  • Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13:416-25; PMID:23414709; http://dx.doi.org/10.1016/S1473-3099(13)70006-9
  • Lecocq H, Parent du Chatelet I, Taha MK, Levy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine 2016; 34: 2240-2250; PMID:27002504
  • Budroni S, Kleinschmidt A, Boucher P, Medini D. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. Vaccine 2016; 34:2579-84; PMID:27083425; http://dx.doi.org/10.1016/j.vaccine.2016.04.009
  • Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013; 31:4968-74; PMID:23954380; http://dx.doi.org/10.1016/j.vaccine.2013.08.006
  • Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, Rappuoli R, Pizza M, Donnelly J. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010; 28:5023-30; PMID:20493284
  • Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051